Managing Early Multiple Sclerosis - A Clinical Update
Neurology
Curriculum:
Multiple Sclerosis Clinical Update
Multiple Sclerosis Clinical Update
Credits:
1 AAFP Prescribed Credit(s) 1 AANP Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 AAFP Prescribed Credit(s) 1 AANP Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
November 30, 2015
November 30, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Neurologists; PCPs; Advanced Practice Clinicians; Managed Care Directors; MS Specialists; and MS Nurse Specialists
Relevant Terms:
Multiple sclerosis
Patricia K. Coyle, MD, FAAN
Patricia K. Coyle, MD, FAAN
Professor and Vice Chair Clinical Affairs
Department of Neurology
SUNY at Stony Brook
Stony Brook, NY
Bio
Patricia K. Coyle, MD, FAAN, FANA, is Professor and Vice Chair (Clinical Affairs) of Neurology, and Director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Medical Center, Stony Brook, New York. She received a BS degree with highest honors from Fordham University, Bronx, New York, and an MD degree from the Johns Hopkins School of Medicine, where she was elected to Alpha Omega Alpha. While at the Johns Hopkins School of Medicine, Dr. Coyle completed a residency and chief residency in neurology, followed by a two-year fellowship in neuroimmunology and neurovirology.
Dr. Coyle then went on to establish a successful research laboratory in addition to building a busy clinical practice at the Stony Brook University Medical Center. Dr. Coyle is the author of numerous articles on clinical and basic research aspects of multiple sclerosis (MS) and neurologic infections and she is recognized as a leading expert on MS and neurologic infections. Her areas of expertise include Lyme disease and neurologic infections, cerebrospinal fluid, therapeutics, and neuroimmunology. Her research has been supported by the National Institutes of Health and other organizations. She is currently involved in a number of therapeutic trials testing new immunotherapies for MS, as well as studies addressing neurologic aspects of Lyme disease.
Dr. Coyle then went on to establish a successful research laboratory in addition to building a busy clinical practice at the Stony Brook University Medical Center. Dr. Coyle is the author of numerous articles on clinical and basic research aspects of multiple sclerosis (MS) and neurologic infections and she is recognized as a leading expert on MS and neurologic infections. Her areas of expertise include Lyme disease and neurologic infections, cerebrospinal fluid, therapeutics, and neuroimmunology. Her research has been supported by the National Institutes of Health and other organizations. She is currently involved in a number of therapeutic trials testing new immunotherapies for MS, as well as studies addressing neurologic aspects of Lyme disease.
In addition to Dr. Coyle's busy clinical and research careers, she has held active leadership positions in a number of national and international organizations and academic societies, including the American Academy of Neurology, American Neurological Association, National MS Society, and the American Board of Psychiatry and Neurology. She lectures widely on MS and neurologic infections to national and international audiences.
Fred D. Lublin, MD
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dicknson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Bio
Fred D. Lublin, M.D. is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.
As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS.
Dr. Lublin was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He is also Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee, a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation, has chaired a task force on the ethics of placebo-controlled trials in MS. is a member of the international panel that periodically redefines the diagnostic criteria for MS, co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee, a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system, and a member of the National MS Society National Board of Directors, whereby Dr. Lublin and his colleagues have re-defined the clinical course definitions of MS, updated in 2014.
Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He is the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis.
Clyde E. Markowitz, MD
Clyde E. Markowitz, MD
Director
Multiple Sclerosis Center at Penn
Associate Professor of Neurology
Hospital of the University of Pennsylvania
Philadelphia, PA
Bio
Clyde E. Markowitz, M.D. received his medical degree from the Columbia University College of Physicians and Surgeons in New York, NY. He also completed his residency, post-doctoral research, and a clinical fellowship at the Neurological Institute at Columbia University College of Physicians and Surgeons. He is currently an associate professor of neurology at the University of Pennsylvania School of Medicine in Philadelphia, PA, Director of the MS Center at the Hospital of the University of Pennsylvania, and Division Chief, Multiple Sclerosis Section, Department of Neurology at the Hospital of the University of Pennsylvania.As a neurologist, Dr. Markowitz's main area of expertise is in the field of multiple sclerosis (MS) and he is involved with many clinical trials developing new compounds for the treatment of MS. His research interests include utilization of new MRI techniques to study the pathogenesis of MS, and the immunology of MS.
Dr. Markowitz is the author or co-author of a number of publications in journals such as Annals of Neurology and Neurology. He serves as an ad hoc reviewer for Annals of Neurology, Archives of Neurology, Journal of the Neurological Sciences, Neuro-Rehabilitation, Neural Repair, Journal of Clinical Immunology, and The Consultant. Additionally, Dr. Markowitz is a member of the American Academy of Neurology and currently serves as the Chairman of the Clinical Advisory Committee of the Delaware Valley Chapter of the National Multiple Sclerosis Society.
Aaron E. Miller, MD
Aaron E. Miller, MD
Professor of Neurology
Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Bio
Dr. Miller graduated from Brandeis University in 1964 and received his MD degree from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at Einstein. During this time, he was the recipient of a fellowship from the National MS Society. In March, 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai. For 23 years prior to that, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY where he continues to serve as co-director of the MS Care Center. Dr. Miller is also a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York.
Dr. Miller became the chief medical officer of the National MS Society in October 2001 and continues to serve as its senior medical advisor. He has participated in numerous clinical trials of new treatments for MS. He has authored two books, Multiple Sclerosis in Clinical Practice, with colleagues Fred Lublin and Patricia Coyle and Neuroimmunology as part of the What Do I Do Now? Series with Tracy DeAngelis. He has also published more than 70 articles in peer-reviewed journal, as well as many chapters on MS and other neurological subjects.
Dr. Miller is also very active with the American Academy of Neurology, for which he served as a member of the Board of Directors from 2009—2013 and currently serves at the Secretary of that Board. He recently completed 10 years as Editor of Continuum, the bimonthly continuing education publication of the AAN, and currently serves as Editor of Continuum Audio. He was a member of the Education Committee from 1989—2009 and the Meeting Management Committee from 1997--2009. From 1997—2003, he served as Co-chairman of the Education Committee and Chairman of the Annual Meeting Subcommittee. Prior to assuming that position, he served as chairman of the Program Accreditation and Development Subcommittee.
Dr. Miller has been cited by New York Magazine in its list of Top Doctors from 2008—2012 and has been included in Castle Connolly's book of America's Top Doctors in 2009--2014.
Dr. Miller became the chief medical officer of the National MS Society in October 2001 and continues to serve as its senior medical advisor. He has participated in numerous clinical trials of new treatments for MS. He has authored two books, Multiple Sclerosis in Clinical Practice, with colleagues Fred Lublin and Patricia Coyle and Neuroimmunology as part of the What Do I Do Now? Series with Tracy DeAngelis. He has also published more than 70 articles in peer-reviewed journal, as well as many chapters on MS and other neurological subjects.
Dr. Miller is also very active with the American Academy of Neurology, for which he served as a member of the Board of Directors from 2009—2013 and currently serves at the Secretary of that Board. He recently completed 10 years as Editor of Continuum, the bimonthly continuing education publication of the AAN, and currently serves as Editor of Continuum Audio. He was a member of the Education Committee from 1989—2009 and the Meeting Management Committee from 1997--2009. From 1997—2003, he served as Co-chairman of the Education Committee and Chairman of the Annual Meeting Subcommittee. Prior to assuming that position, he served as chairman of the Program Accreditation and Development Subcommittee.
Dr. Miller has been cited by New York Magazine in its list of Top Doctors from 2008—2012 and has been included in Castle Connolly's book of America's Top Doctors in 2009--2014.
| 1. | Discuss current clinical evidence supporting treatment plans for patients with MS | 2. | Define the efficacy and safety of current and emerging therapies for treating patients with MS |
| 3. | Compare and contrast current and emerging therapies for MS |
| 1. | Discuss current clinical evidence supporting treatment plans for patients with MS |
| 2. | Define the efficacy and safety of current and emerging therapies for treating patients with MS |
| 3. | Compare and contrast current and emerging therapies for MS |
Co-provided by Albert Einstein College of Medicine and Antidote Education Company
This activity is made possible by independent educational grants from Biogen Idec, Teva Pharmaceuticals, and Sanofi-Genzyme, a Sanofi company.
Course Director
Michael O. Fleming, MD, FAAFP
Assistant Clinical Professor of Family Medicine and Comprehensive Care
LSU Health Science Center School of Medicine
Shreveport, LA
Assistant Clinical Professor of Family Medicine
Shreveport, LA
Assistant Clinical Professor of Family Medicine
Department of Family and Community Medicine
Tulane University Medical School
New Orleans, LA
Chief Medical Officer
Antidote Education Company
Dallas, TX
Dr. Fleming is a founder of Antidote and serves as Chief Medical Officer. He is a Clinical Associate Professor of Family Medicine at LSU Health Science Center in Shreveport and Clinical Assistant Professor of Family and Community Medicine at Tulane University School of Medicine. Dr. Fleming has more than 29 years of medical practice experience and is past President of the American Academy of Family Physicians and the Louisiana Academy of Family Physicians; and was founding President of the Louisiana Health Care Quality Forum.
Peer Reviewer
David Myland Kaufman, MD
Professor, The Saul R. Korey Department of Neurology
Professor, Department of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY
CONFLICT OF INTEREST DISCLOSURE POLICY
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Victor B. Hatcher, PhD, and the staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine have no conflict of interest with commercial interests relevant to this educational activity.
The planning staff of Antidote Medical Education Company and RealCME have no commercial relationships to disclose.
Individuals in a position to control the content of this activity reported the following relevant financial relationships with commercial interests:
Chairperson
Patricia K. Coyle, MD has disclosed the following relationships:
Grant(s)/Research: Actelion, Novartis, and Opexa
Consultant Fee(s): AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, and Teva
Faculty
Consultant Fee(s): AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, and Teva
Faculty
Fred D. Lublin, MD has disclosed the following relationships:
Grant(s)/Research: Acorda Therapeutics, Inc, Biogen Idec, Celgene, Genzyme
Novartis Pharmaceuticals Corp., Sanofi, Teva Neuroscience, Inc., and Transparency Live Sciences
Consultant Fee(s): Acorda Therapeutics, Inc., Actelion, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Celgene, Coronad Bioscience, EMD Serono, Inc., Forward Pharma, Genentech, Genzyme, Johnson & Johnson, Medimmune, Novartis Pharmaceuticals Corp., Questocor, Receptos, Revalesio, Roche, Sanofi, Teva Neuroscience, Inc., and Xenoport
Stockholder: Cognition Pharmaceuticals, Inc.
Speakers' Bureau: Genzyme
Clyde E. Markowitz, MD has disclosed the following relationships:
Consultant Fee(s): Bayer, Biogen Idec, EMD Serono, Novartis, Genetech, Genzyme, Roche, Sanofi-Aventis, and Teva
Grant(s)/Research: Acorda Therapeutics, Inc, Biogen Idec, Celgene, Genzyme
Novartis Pharmaceuticals Corp., Sanofi, Teva Neuroscience, Inc., and Transparency Live Sciences
Consultant Fee(s): Acorda Therapeutics, Inc., Actelion, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Celgene, Coronad Bioscience, EMD Serono, Inc., Forward Pharma, Genentech, Genzyme, Johnson & Johnson, Medimmune, Novartis Pharmaceuticals Corp., Questocor, Receptos, Revalesio, Roche, Sanofi, Teva Neuroscience, Inc., and Xenoport
Stockholder: Cognition Pharmaceuticals, Inc.
Speakers' Bureau: Genzyme
Clyde E. Markowitz, MD has disclosed the following relationships:
Consultant Fee(s): Bayer, Biogen Idec, EMD Serono, Novartis, Genetech, Genzyme, Roche, Sanofi-Aventis, and Teva
Contracted Research: Genentech, Biogen Idec, EMD-Serono, Teva, Opexa, and Novartis
Aaron E. Miller, MD has disclosed the following relationships:
Grant(s)/Research: Biogen Idec, Genentech, Genzyme/Sanofi-Aventis, Novartis, Questocor, and Roche
Consultant Fee(s): Accordant Health Services, Acorda, Biogen Idec, EMD Serono, Inc., Genzyme/Sanofi-Aventis, Glaxo Smith Kline, Novartis, Questocor, Roche, and Teva
The following individuals have indicated no conflict of interest disclosures to report:
Michael O. Fleming, MD FAAFP (Course Director)
David Myland Kaufman, MD (Peer Reviewer)
Aaron E. Miller, MD has disclosed the following relationships:
Grant(s)/Research: Biogen Idec, Genentech, Genzyme/Sanofi-Aventis, Novartis, Questocor, and Roche
Consultant Fee(s): Accordant Health Services, Acorda, Biogen Idec, EMD Serono, Inc., Genzyme/Sanofi-Aventis, Glaxo Smith Kline, Novartis, Questocor, Roche, and Teva
The following individuals have indicated no conflict of interest disclosures to report:
Michael O. Fleming, MD FAAFP (Course Director)
David Myland Kaufman, MD (Peer Reviewer)
Josh Kilbridge (Editor)
Matthew Fleming (Vice President, Antidote Education Company)
ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
ACCME: Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Matthew Fleming (Vice President, Antidote Education Company)
UNAPPROVED PRODUCT USE
The faculty have indicated that this enduring material does not include discussion of the unlabeled/investigational use of a commercial product or device.
Albert Einstein College of Medicine, Antidote Education Company, Biogen Idec, Teva Pharmaceuticals, and Sanofi-Genzyme, a Sanofi company, do not recommend the use of any agent outside the labeled indications.
DISCLAIMER
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine, Montefiore Medical Center, Antidote Education Company, Biogen Idec, Teva Pharmaceuticals, and Sanofi-Genzyme, a Sanofi company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
ACCME: Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP: This Enduring Material activity, Managing Early Multiple Sclerosis - A Clinical Update, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians (AAFP). Term of approval begins 06/12/2015. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP: This program is approved for 1.00 contact hour(s) of continuing education by the American Association of Nurse Practitioners (AANP). Program ID 1505235. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
METHOD OF PARTICIPATION
There is no fee to participate in this activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Certificates can be printed immediately. The participant may take the test until successfully passed. Credit is available through November 29, 2016.
For questions related to this CME activity, please contact Albert Einstein College of Medicine either at cme@montefiore.org or call 718-920-6674.
For technical questions related to this activity, please contact RealCME at http://www.realcme.com/cms/support-center.
Release Date: November 30, 2015
Expiration Date: November 29, 2016
COPYRIGHT INFORMATION
Copyright © 2015 Albert Einstein College of Medicine and Antidote Education Company. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
PRIVACY POLICY
Albert Einstein College of Medicine, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx.
Albert Einstein College of Medicine, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above |
